Lilly Asia Ventures and Sinopharm Healthcare Fund co-led the round that will fund a phase 3 trial for Ansun Biopharma's parainfluenza treatment.
US-based respiratory therapy developer Ansun Biopharma closed an $85m series A round yesterday co-led by Sinopharm Healthcare Fund and Lilly Asia Ventures, respective subsidiaries of pharmaceutical firms Sinopharm and Eli Lilly.
The corporates invested together with Lyfe Capital, Yuanming Capital, Matrix Partners China, 3E Bioventures Capital, Oceanpine Capital, VI Ventures and Joincap Investment.
Founded in 2002 as NexBio, Ansun Biopharma is working on anti-viral treatments for respiratory conditions. The funding will support an upcoming phase 3 clinical trial for DAS181,…
